Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE LEBER CONGENITAL AMAUROSIS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 DISEASE TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PIPELINE ANALYSIS FOR EUROPE LEBER CONGENTIAL AMAUROSIS MARKET
4.2 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: REGULATIONS
4.3 PESTEL ANALYSIS
4.4 PORTERS FIVE FORCES
5 EPIDEMIOLOGY
6 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASE IN INCIDENCE AND PREVALENCE OF RPE65 GENE-MEDIATED IN RETINAL DISEASES
6.1.2 INCREASE IN PIPELINE PRODUCTS AND CLINICAL TRIALS
6.1.3 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYER
6.2 RESTRAINTS
6.2.1 LACK OF QUALIFIED PROFESSIONALS
6.2.2 HIGH COSTS ASSOCIATED WITH TREATMENT AND PROCEDURE
6.3 OPPORTUNITIES
6.3.1 INCREASE IN GOVERNMENT INITIATIVES TOWARD LEBER CONGENITAL AMAUROSIS
6.3.2 INCREASE IN THE TREATMENT-SEEKING RATE
6.3.3 FAVOURABLE REIMBURSEMENT POLICIES FOR THE TREATMENT
6.4 CHALLENGES
6.4.1 RISKS ASSOCIATED WITH LEBER CONGENITAL AMAUROSIS GENE THERAPY
6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR GENE THERAPY PRODUCTS
7 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE
7.1 OVERVIEW
7.2 INFANTILE TYPE
7.3 JUVENILE TYPE
7.4 OTHERS
8 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE
8.1 OVERVIEW
8.2 THERAPY
8.2.1 GENE THERAPY
8.2.1.1 LUXTURNA
8.2.2 RETINAL PROSTHETIC
8.2.3 NEUROPROTECTIVE AGENTS
8.2.3.1 VITAMIN A PALMITATE
8.2.3.2 DOCOSAHEXAENOIC ACID
8.2.3.3 LUTEIN
8.2.3.4 OTHERS
8.2.4 OTHERS
8.3 DIAGNOSIS
8.3.1 CLINICAL DIAGNOSIS
8.3.1.1 ELECTROPHYSIOLOGICAL TESTS
8.3.1.1.1 FULL-FIELD ELECTRORETINOGRAM (ERG)
8.3.1.1.2 DARK ADAPTOMETRY (DA)
8.3.1.2 RETINAL IMAGING
8.3.1.2.1 OPTICAL COHERENCE TOMOGRAPHY (OCT)
8.3.1.2.2 FUNDUS AUTOFLUORESCENCE
8.3.1.2.3 SCANNING LASER OPHTHALMOSCOPY (SLO)
8.3.1.2.4 ADAPTIVE OPTICS (AO) IMAGING
8.3.1.2.5 CONVENTIONAL COLOR FUNDUS IMAGING
8.3.1.3 VISUAL FIELD TEST
8.3.1.3.1 COMPUTERIZED VISUAL FIELD TESTS
8.3.1.3.2 MANUAL FIELD TEST
8.3.1.4 CLINICAL EYE EXAMINATION
8.3.1.4.1 SLIT LAMP
8.3.1.4.2 INDIRECT OPHTHALMOSCOPY
8.3.1.4.3 REFRACTION TEST
8.3.1.4.4 DILATION EXAM
8.3.1.5 OTHERS
8.3.2 GENETIC DIAGNOSIS
9 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 SPECIALITY CLINICS
9.4 AMBULATORY SURGICAL CENTERS
9.5 HOME HEALTHCARE
9.6 OTHERS
10 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 RETAIL SALES
10.2.1.1 HOSPITAL PHARMACIES
10.2.1.2 RETAIL PHARMACIES
10.2.1.3 OTHERS
10.3 DIRECT TENDER
11 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY REGION
11.1 EUROPE
11.1.1 GERMANY
11.1.2 FRANCE
11.1.3 U.K.
11.1.4 RUSSIA
11.1.5 ITALY
11.1.6 SPAIN
11.1.7 NETHERLAND
11.1.8 SWITZERLAND
11.1.9 POLAND
11.1.10 TURKEY
11.1.11 AUSTRIA
11.1.12 HUNGARY
11.1.13 NORWAY
11.1.14 IRELAND
11.1.15 LITHUANIA
11.1.16 REST OF EUROPE
12 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: EUROPE
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 SPARK THERAPEUTICS, INC
14.1.1 COMPANY SNAPSHOT
14.1.2 COMPANY SHARE ANALYSIS
14.1.3 PRODUCT PORTFOLIO
14.1.4 RECENT DEVELOPMENT
14.1.4.1 EU AUTHORIZATION
14.2 OPTOS
14.2.1 COMPANY SNAPSHOT
14.2.2 COMPANY SHARE ANALYSIS
14.2.3 PRODUCT PORTFOLIO
14.2.4 RECENT DEVELOPMENT
14.2.4.1 PRODUCT APPROVAL
14.3 CD GENOMICS
14.3.1 COMPANY SNAPSHOT
14.3.2 COMPANY SHARE ANALYSIS
14.3.3 PRODUCT PORTFOLIO
14.3.4 RECENT DEVELOPMENT
14.4 BLUEPRINTS GENETICS OY (A SUBSIDIARY OF QUEST DIAGNOSTICS)
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.4.5.1 COLLABORATION
14.5 LKC TECHNOLOGIES, INC
14.5.1 COMPANY SNAPSHOT
14.5.2 COMPANY SHARE ANALYSIS
14.5.3 PRODUCT PORTFOLIO
14.5.4 RECENT DEVELOPMENT
14.5.4.1 PRODUCT APPROVAL
14.5.5 PRODUCT APPROVAL
14.6 AGTC
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENTS
14.6.4.1 AGREEMENT
14.7 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.)
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENTS
14.8 ASTELLAS PHARMA INC.
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENT
14.9 ATSENA THERAPEUTICS
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENT
14.1 CENTOGENE N.V.
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENT
14.10.4.1 PRODUCT LAUNCH
14.11 COAVE THERAPEUTICS
14.11.1 COMPANY SNAPSHOT
14.11.2 PRODUCT PORTFOLIO
14.11.3 RECENT DEVELOPMENT
14.12 EDITAS MEDICINE
14.12.1 COMPANY SNAPSHOT
14.12.2 REVENUE ANALYSIS
14.12.3 PRODUCT PORTFOLIO
14.12.4 RECENT DEVELOPMENTS
14.12.4.1 DATA & TRAIL DATA PRESENTATION
14.13 ELUMINEX BIOSCIENCES
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 GYROSCOPE THERAPEUTICS LIMITED
14.14.1 COMPANY SNAPSHOT
14.14.2 PRODUCT PORTFOLIO
14.14.3 RECENT DEVELOPMENTS
14.15 INVITAE CORPORATION
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENTS
14.15.4.1 NEW FACILITY
14.15.4.2 EXPANSION
14.16 IVERIC BIO.
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENT
14.17 KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD.
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENTS
14.18 MEIRAGTX LIMITED
14.18.1 COMPANY SNAPSHOT
14.18.2 PRODUCT PORTFOLIO
14.18.3 RECENT DEVELOPMENT
14.19 METROVISION
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENT
14.19.3.1 FDA CLEARANCE APPROVAL
14.2 OCUGEN INC.
14.20.1 COMPANY SNAPSHOT
14.20.2 PRODUCT PORTFOLIO
14.20.3 RECENT DEVELOPMENT
14.21 OKUVISION
14.21.1 COMPANY SNAPSHOT
14.21.2 PRODUCT PORTFOLIO
14.21.3 RECENT DEVELOPMENTS
14.21.3.1 APPROVAL
14.22 PROQR THERAPEUTICS
14.22.1 COMPANY SNAPSHOT
14.22.2 PRODUCT PORTFOLIO
14.22.3 RECENT DEVELOPMENTS
14.23 REGENXBIO INC.
14.23.1 COMPANY SNAPSHOT
14.23.2 REVENUE ANALYSIS
14.23.3 PRODUCT PORTFOLIO
14.23.4 RECENT DEVELOPMENTS
14.24 SPARINGVISION
14.24.1 COMPANY SNAPSHOT
14.24.2 PRODUCT PORTFOLIO
14.24.3 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
List of Table
TABLE 1 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 2 EUROPE INFANTILE TYPE IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 EUROPE JUVENILE TYPE IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 EUROPE OTHERS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 6 EUROPE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 EUROPE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 8 EUROPE GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 9 EUROPE NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 10 EUROPE DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 EUROPE DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 12 EUROPE CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 13 EUROPE ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 EUROPE RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 EUROPE VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 EUROPE CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 18 EUROPE HOSPITALS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE SPECIALITY CLINICS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 EUROPE AMBULATORY SURGICAL CENTERS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 EUROPE HOME HEALTHCARE IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 EUROPE OTHERS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 24 EUROPE RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 EUROPE RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 26 EUROPE DIRECT TENDER IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 28 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 29 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 30 EUROPE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 31 EUROPE GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 32 EUROPE NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 33 EUROPE DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 34 EUROPE CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 35 EUROPE RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 36 EUROPE ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 37 EUROPE VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 38 EUROPE CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 39 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 40 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 41 EUROPE RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 42 GERMANY LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 43 GERMANY LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 44 GERMANY THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 45 GERMANY GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 46 GERMANY NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 47 GERMANY DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 48 GERMANY CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 GERMANY RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 GERMANY ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 51 GERMANY VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 52 GERMANY CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 53 GERMANY LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 54 GERMANY LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 55 GERMANY RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 56 FRANCE LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 57 FRANCE LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 58 FRANCE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 59 FRANCE GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 60 FRANCE NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 FRANCE DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 62 FRANCE CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 63 FRANCE RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 FRANCE ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 FRANCE VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 66 FRANCE CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 67 FRANCE LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 68 FRANCE LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 69 FRANCE RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 70 U.K. LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 71 U.K. LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 72 U.K. THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 73 U.K. GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 74 U.K. NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 75 U.K. DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 76 U.K. CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 77 U.K. RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 78 U.K. ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 U.K. VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 U.K. CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 81 U.K. LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 82 U.K. LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 83 U.K. RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 84 RUSSIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 85 RUSSIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 86 RUSSIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 87 RUSSIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 88 RUSSIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 89 RUSSIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 90 RUSSIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 91 RUSSIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 92 RUSSIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 93 RUSSIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 94 RUSSIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 95 RUSSIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 96 RUSSIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 97 RUSSIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 98 ITALY LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 99 ITALY LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 100 ITALY THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 101 ITALY GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 102 ITALY NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 103 ITALY DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 104 ITALY CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 105 ITALY RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 106 ITALY ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 107 ITALY VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 108 ITALY CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 109 ITALY LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 110 ITALY LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 111 ITALY RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 112 SPAIN LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 113 SPAIN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 114 SPAIN THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 115 SPAIN GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 116 SPAIN NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 117 SPAIN DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 118 SPAIN CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 119 SPAIN RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 120 SPAIN ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 121 SPAIN VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 122 SPAIN CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 123 SPAIN LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 124 SPAIN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 125 SPAIN RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 126 NETHERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 127 NETHERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 128 NETHERLAND THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 129 NETHERLAND GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 130 NETHERLAND NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 131 NETHERLAND DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 132 NETHERLAND CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 133 NETHERLAND RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 134 NETHERLAND ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 135 NETHERLAND VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 136 NETHERLAND CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 137 NETHERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 138 NETHERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 139 NETHERLAND RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 140 SWITZERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 141 SWITZERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 142 SWITZERLAND THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 143 SWITZERLAND GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 144 SWITZERLAND NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 145 SWITZERLAND DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 146 SWITZERLAND CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 147 SWITZERLAND RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 148 SWITZERLAND ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 149 SWITZERLAND VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 150 SWITZERLAND CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 151 SWITZERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 152 SWITZERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 153 SWITZERLAND RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 154 POLAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 155 POLAND LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 156 POLAND THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 157 POLAND GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 158 POLAND NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 159 POLAND DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 160 POLAND CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 161 POLAND RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 162 POLAND ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 163 POLAND VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 164 POLAND CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 165 POLAND LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 166 POLAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 167 POLAND RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 168 TURKEY LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 169 TURKEY LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 170 TURKEY THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 171 TURKEY GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 172 TURKEY NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 173 TURKEY DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 174 TURKEY CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 175 TURKEY RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 176 TURKEY ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 177 TURKEY VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 178 TURKEY CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 179 TURKEY LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 180 TURKEY LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 181 TURKEY RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 182 AUSTRIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 183 AUSTRIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 184 AUSTRIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 185 AUSTRIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 186 AUSTRIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 187 AUSTRIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 188 AUSTRIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 189 AUSTRIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 190 AUSTRIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 191 AUSTRIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 192 AUSTRIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 193 AUSTRIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 194 AUSTRIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 195 AUSTRIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 196 HUNGARY LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 197 HUNGARY LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 198 HUNGARY THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 199 HUNGARY GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 200 HUNGARY NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 201 HUNGARY DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 202 HUNGARY CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 203 HUNGARY RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 204 HUNGARY ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 205 HUNGARY VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 206 HUNGARY CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 207 HUNGARY LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 208 HUNGARY LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 209 HUNGARY RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 210 NORWAY LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 211 NORWAY LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 212 NORWAY THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 213 NORWAY GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 214 NORWAY NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 215 NORWAY DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 216 NORWAY CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 217 NORWAY RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 218 NORWAY ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 219 NORWAY VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 220 NORWAY CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 221 NORWAY LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 222 NORWAY LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 223 NORWAY RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 224 IRELAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 225 IRELAND LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 226 IRELAND THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 227 IRELAND GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 228 IRELAND NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 229 IRELAND DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 230 IRELAND CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 231 IRELAND RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 232 IRELAND ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 233 IRELAND VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 234 IRELAND CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 235 IRELAND LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 236 IRELAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 237 IRELAND RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 238 LITHUANIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 239 LITHUANIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 240 LITHUANIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 241 LITHUANIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 242 LITHUANIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 243 LITHUANIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 244 LITHUANIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 245 LITHUANIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 246 LITHUANIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 247 LITHUANIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 248 LITHUANIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 249 LITHUANIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 250 LITHUANIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 251 LITHUANIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 252 REST OF EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: SEGMENTATION
FIGURE 2 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: END USER GRID
FIGURE 9 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: SEGMENTATION
FIGURE 11 RISING GOVERNMENT AWARENESS PROGRAMS ABOUT THE INHERITED RETINAL DISEASE IS EXPECTED TO DRIVE THE EUROPE LEBER CONGENITAL AMAUROSIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INFANTILE TYPE IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE LEBER CONGENITAL AMAUROSIS MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE LEBER CONGENITAL AMAUROSIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FOR THE EUROPE LEBER CONGENITAL AMAUROSIS MARKET
FIGURE 15 PROPORTION OF RPE65 GENE MUTATION IN CLINICALLY DIAGNOSED LCA PATIENTS
FIGURE 16 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, 2021
FIGURE 17 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, 2022-2029 (USD MILLION)
FIGURE 18 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, CAGR (2022-2029)
FIGURE 19 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 20 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, 2021
FIGURE 21 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 22 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 23 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 24 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, 2021
FIGURE 25 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 26 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 27 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 28 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 29 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 30 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 31 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 32 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: SNAPSHOT (2021)
FIGURE 33 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2021)
FIGURE 34 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 35 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 36 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE (2022-2029)
FIGURE 37 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: COMPANY SHARE 2021 (%)
